ABSTRACT
Primordial follicles, the main source of oocytes in the ovary, are essential for the maintenance of fertility throughout the reproductive lifespan. To the best of our knowledge, there are no reports describing the effect of anethole on this important ovarian follicle population. The aim of the study was to investigate the effect of different anethole concentrations on the in vitro culture of caprine preantral follicles enclosed in ovarian tissue. Randomized ovarian fragments were fixed immediately (non-cultured treatment) or distributed into five treatments: α-MEM+ (cultured control), α-MEM+ supplemented with ascorbic acid at 50 μg/mL (AA), and anethole at 30 (AN30), 300 (AN300), or 2000 µg/mL (AN2000), for 1 or 7 days. After 7 days of culture, a significantly higher percentage of morphologically normal follicles was observed when anethole at 2000 μg/mL was used. For both culture times, a greater percentage of growing follicles was observed with the AN30 treatment compared to AA and AN2000 treatments. Anethole at 30 and 2000 µg/mL concentrations at days 1 and 7 of culture resulted in significantly larger follicular diameter than in the cultured control treatment. Anethole at 30 µg/mL concentration at day 7 showed significantly greater oocyte diameter than the other treatments, except when compared to the AN2000 treatment. At day 7 of culture, levels of reactive oxygen species (ROS) were significantly lower in the AN30 treatment than the other treatments. In conclusion, supplementation of culture medium with anethole improves survival and early follicle development at different concentrations in the caprine species.
Subject(s)
Animals , Female , Oxidative Stress/drug effects , In Vitro Oocyte Maturation Techniques/veterinary , Ovarian Follicle/growth & development , Anisoles/pharmacology , Goats , Immunohistochemistry , Random Allocation , Culture Media , Dose-Response Relationship, Drug , In Vitro Oocyte Maturation Techniques/methods , Ovarian Follicle/drug effects , Anisoles/administration & dosageABSTRACT
La fibrilación auricular (FA) es la arritmia sostenida más frecuente. La cardioversión es uno de los tratamientos de primera elección para la finalización de la FA de reciente comienzo, especialmente la farmacológica, ya que tiene la ventaja de no utilizar sedación. El vernakalant es un antiarrítmico que actúa selectivamente sobre la aurícula, inhibiendo las corrientes de potasio, con mínimo bloqueo de la corriente ventricular IKr. Este antiarrítmico ha sido aprobado recientemente por la Unión Europea para la cardioversión farmacológica de la FA de reciente comienzo. El objetivo de esta revisión es analizar las características farmacocinéticas y farmacodinámicas del vernakalant, y demostrar la seguridad y eficacia del mismo para la conversión de la FA a ritmo sinusal.
Atrial fibrillation (AF) is the most common sustained arrhythmia. Cardioversion is considered one of the best treatments for recent onset AF, especially with drugs for avoiding sedation. Vernakalant is a novel antiarrhythmic that acts selectively in the atrium, and inhibits potassium currents, with minor blockade of IKr currents in the ventricle. It has been recently approved for pharmacological cardioversion of recent-onset AF in the European Union. The aim of this review is to analyze the pharmacokinetic and pharmacodynamic of vernakalant, and to show the efficacy and safety of this drug for the conversion of AF to sinus rhythm.